Colorectal cancer (CRC) is the third most common cancer in the United States. The 2017 American Cancer Society report provides updated statistics on CRC incidence, mortality, and trends. CRC incidence rates are highest in Alaska Natives and non-Hispanic blacks (NHBs) and lowest in Asian Americans/Pacific Islanders (APIs). Rates are 30-40% higher in men than in women. From 2000 to 2013, incidence rates in adults aged ≥50 years declined by 32%, with the largest drop in distal tumors in those aged ≥65 years and the smallest in rectal tumors in those aged 50-64 years. Overall, CRC incidence in individuals aged ≥50 years declined in every state except Arkansas. CRC incidence in adults <50 years increased by 22%, driven by distal colon and rectum tumors. CRC mortality rates declined by 34% in those aged ≥50 years but increased by 13% in those <50 years. Mortality rates are 40% higher in men than in women. Racial/ethnic disparities persist, with NHBs having higher incidence and mortality rates than NHWs and APIs. Socioeconomic factors, screening disparities, and access to care contribute to these disparities. CRC incidence in Alaska Natives is 80% higher than in NHBs. Geographic disparities exist, with higher rates in the South and Midwest. CRC screening prevalence in adults aged ≥50 years was 76% in Massachusetts and 58% in Wyoming in 2014. CRC incidence in adults <50 years increased by 22% from 2000 to 2013. Survival rates for CRC have improved, with 5-year relative survival rates increasing from 51% to 66% for colon cancer and 48% to 68% for rectal cancer. Survival is higher for younger patients and those with localized disease. Progress in reducing CRC mortality has been slower in high-poverty areas. The report emphasizes the need for increased screening, healthier lifestyles, and equitable access to care to reduce disparities and improve outcomes. Achieving a 80% screening prevalence by 2018 could prevent 277,000 CRC cases and 203,000 deaths by 2030.Colorectal cancer (CRC) is the third most common cancer in the United States. The 2017 American Cancer Society report provides updated statistics on CRC incidence, mortality, and trends. CRC incidence rates are highest in Alaska Natives and non-Hispanic blacks (NHBs) and lowest in Asian Americans/Pacific Islanders (APIs). Rates are 30-40% higher in men than in women. From 2000 to 2013, incidence rates in adults aged ≥50 years declined by 32%, with the largest drop in distal tumors in those aged ≥65 years and the smallest in rectal tumors in those aged 50-64 years. Overall, CRC incidence in individuals aged ≥50 years declined in every state except Arkansas. CRC incidence in adults <50 years increased by 22%, driven by distal colon and rectum tumors. CRC mortality rates declined by 34% in those aged ≥50 years but increased by 13% in those <50 years. Mortality rates are 40% higher in men than in women. Racial/ethnic disparities persist, with NHBs having higher incidence and mortality rates than NHWs and APIs. Socioeconomic factors, screening disparities, and access to care contribute to these disparities. CRC incidence in Alaska Natives is 80% higher than in NHBs. Geographic disparities exist, with higher rates in the South and Midwest. CRC screening prevalence in adults aged ≥50 years was 76% in Massachusetts and 58% in Wyoming in 2014. CRC incidence in adults <50 years increased by 22% from 2000 to 2013. Survival rates for CRC have improved, with 5-year relative survival rates increasing from 51% to 66% for colon cancer and 48% to 68% for rectal cancer. Survival is higher for younger patients and those with localized disease. Progress in reducing CRC mortality has been slower in high-poverty areas. The report emphasizes the need for increased screening, healthier lifestyles, and equitable access to care to reduce disparities and improve outcomes. Achieving a 80% screening prevalence by 2018 could prevent 277,000 CRC cases and 203,000 deaths by 2030.